E2F2 is a sequence-specific DNA-binding transcription factor that regulates cell cycle progression from G1 to S phase by cooperatively binding E2 recognition sites in target gene promoters through interaction with DP proteins [UniProt]. E2F2 functions as a critical regulator of cellular proliferation and metabolic reprogramming in cancer. Mechanistically, E2F2 directly binds promoter regions to activate oncogenic transcripts including c-Myc, CCNE1, CCNE2, MCM5, CDK1, and UBE2S 12, while simultaneously repressing metabolic genes like CPT2 to establish lipid-rich tumor environments 3. E2F2 exhibits dysregulated expression across multiple malignancies including hepatocellular carcinoma, glioma, and renal cell carcinoma, where it promotes tumor cell proliferation, angiogenesis, and invasiveness 4. Disease relevance extends beyond cancer; in macrophages, E2F2 suppresses metabolic dysfunction-associated steatohepatitis progression by inhibiting SLC7A5 transcription and regulating amino acid metabolism 5. E2F2 also participates in immune evasion pathways, with exosomal LINC01232 promoting E2F2 nuclear entry to activate NBR1 and drive MHC-I degradation in glioma 6. Clinically, E2F2 emerges as a therapeutic target; molecular glues like bufalin induce E2F2 degradation via atypical E3 ligase ZFP91 to suppress hepatocellular carcinoma growth 1, while CDK4/6 inhibitors reduce E2F2 activity in metabolic disease contexts 5.